Connect Biopharma Holdings (CNTB) Free Cash Flow (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted Free Cash Flow of -$16.0 million for Q1 2026, down 39.92% sequentially from -$11.4 million in Q4 2025, and down 59.39% YoY from -$39.4 million in Q1 2025.
Connect Biopharma Holdings (CNTB) Free Cash Flow (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has reported Free Cash Flow for 3 years, with the latest figure at -$16.0 million in Q1 2026.
- Quarterly Free Cash Flow fell 59.39% year-over-year to -$16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.8 million (down 70.88% YoY) and the FY2025 annual result came in at -$51.8 million, down 112.67% from the prior year.
- Free Cash Flow declined to -$16.0 million in Q1 2026 per CNTB's latest filing, from -$11.4 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$592000.0 in Q1 2024 and troughed at -$17.4 million in Q3 2025.
- A 3-year average of -$10.2 million and a median of -$11.4 million in 2025 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 32.58% in 2025, down 1595.95% in 2025.
- Over 3 years, Free Cash Flow stood at -$2.6 million in 2024, then tumbled by 334.54% to -$11.4 million in 2025, then tumbled by 39.92% to -$16.0 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$16.0 million, -$11.4 million, and -$17.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Connect Biopharma Holdings | 148.41 Mn | 148.41 Mn | - | -15.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.92 Mn |
| Jun 30, 2026 | -15.92 Mn |
| Mar 31, 2026 | -16.00 Mn |
| Mar 31, 2026 | -16.00 Mn |
| Dec 31, 2025 | -11.44 Mn |
| Dec 31, 2025 | -11.44 Mn |
| Sep 30, 2025 | -17.44 Mn |
| Sep 30, 2025 | -17.44 Mn |
| Jun 30, 2025 | -12.89 Mn |
| Jun 30, 2025 | -12.89 Mn |
| Mar 31, 2025 | -10.04 Mn |
| Mar 31, 2025 | -10.04 Mn |
| Dec 31, 2024 | -2.63 Mn |
| Dec 31, 2024 | -2.63 Mn |
| Sep 30, 2024 | -13.15 Mn |
| Sep 30, 2024 | -13.15 Mn |
| Jun 30, 2024 | -7.98 Mn |
| Jun 30, 2024 | -7.98 Mn |
| Mar 31, 2024 | -592,000.00 |
| Mar 31, 2024 | -592,000.00 |